Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,327 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ocrelizumab depletes T-lymphocytes more than rituximab in multiple sclerosis.
Capasso N, Nozzolillo A, Scalia G, Lanzillo R, Carotenuto A, De Angelis M, Petruzzo M, Saccà F, Russo CV, Brescia Morra V, Moccia M. Capasso N, et al. Among authors: de angelis m. Mult Scler Relat Disord. 2021 Apr;49:102802. doi: 10.1016/j.msard.2021.102802. Epub 2021 Jan 28. Mult Scler Relat Disord. 2021. PMID: 33556652
Clinical predictors of Dimethyl Fumarate response in multiple sclerosis: a real life multicentre study.
Lanzillo R, Moccia M, Palladino R, Signoriello E, Carotenuto A, Maniscalco GT, Saccà F, Bonavita S, Russo CV, Iodice R, Petruzzo M, Sinisi L, De Angelis M, Lavorgna L, De Rosa A, Romano F, Orlando V, Ronga B, Florio C, Lus G, Brescia Morra V. Lanzillo R, et al. Among authors: de angelis m, de rosa a. Mult Scler Relat Disord. 2020 Feb;38:101871. doi: 10.1016/j.msard.2019.101871. Epub 2019 Nov 25. Mult Scler Relat Disord. 2020. PMID: 31786463
Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experience.
Zecca C, Bovis F, Novi G, Capobianco M, Lanzillo R, Frau J, Repice AM, Hakiki B, Realmuto S, Bonavita S, Curti E, Brambilla L, Mataluni G, Cavalla P, Di Sapio A, Signoriello E, Barone S, Maniscalco GT, Maietta I, Maraffi I, Boffa G, Malucchi S, Nozzolillo A, Coghe G, Mechi C, Salemi G, Gallo A, Sacco R, Cellerino M, Malentacchi M, De Angelis M, Lorefice L, Magnani E, Prestipino E, Sperli F, Brescia Morra V, Fenu G, Barilaro A, Abbadessa G, Signori A, Granella F, Amato MP, Uccelli A, Gobbi C, Sormani MP. Zecca C, et al. Among authors: de angelis m. Mult Scler. 2020 Oct;26(12):1519-1531. doi: 10.1177/1352458519872889. Epub 2019 Oct 1. Mult Scler. 2020. PMID: 31573386
Peripapillary Vessel Density as Early Biomarker in Multiple Sclerosis.
Cennamo G, Carotenuto A, Montorio D, Petracca M, Moccia M, Melenzane A, Tranfa F, Lamberti A, Spiezia AL, Servillo G, De Angelis M, Petruzzo M, Criscuolo C, Lanzillo R, Brescia Morra V. Cennamo G, et al. Among authors: de angelis m. Front Neurol. 2020 Jun 17;11:542. doi: 10.3389/fneur.2020.00542. eCollection 2020. Front Neurol. 2020. PMID: 32625163 Free PMC article.
Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study.
Buonomo AR, Viceconte G, Calabrese M, De Luca G, Tomassini V, Cavalla P, Maniscalco GT, Ferraro D, Nociti V, Radaelli M, Buscarinu MC, Paolicelli D, Gajofatto A, Annovazzi P, Pinardi F, Di Filippo M, Cordioli C, Zappulo E, Scotto R, Gentile I, Spiezia AL, Petruzzo M, De Angelis M, Brescia Morra V, Solaro C, Gasperini C, Cocco E, Moccia M, Lanzillo R; Raising Italian Researchers in Multiple Sclerosis (RIREMS) study group. Buonomo AR, et al. Among authors: de angelis m, de luca g. J Neurol. 2022 Jun;269(6):3301-3307. doi: 10.1007/s00415-022-11009-x. Epub 2022 Feb 14. J Neurol. 2022. PMID: 35165767 Free PMC article.
1,327 results